LG 101506

Drug Profile

LG 101506

Alternative Names: LG 100754; LG 101506 FA

Latest Information Update: 11 Aug 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly; Ligand Pharmaceuticals
  • Class Phenyl ethers; Small molecules; Unsaturated fatty acids
  • Mechanism of Action Peroxisome proliferator-activated receptor modulators; Retinoid X receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 11 Aug 2006 No development reported - Preclinical for Obesity in USA (unspecified route)
  • 11 Aug 2006 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 14 May 2003 Ligand and Eli Lilly have agreed to a second extention of their collaboration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top